Paraneoplastic movement disorder, autoantibody positive (Q100620)

Paraneoplastic movement disorder seropositive for neural autoantibodies. When these neural antibodies target plasma membrane antigens they are causes of injury (e.g. N-methyl-D-aspartate receptor associated with ovarian teratomas) through multiple effector mechanisms. However, when targeting nuclear or cytoplasmic antigens (e.g. collapsin-response-mediator-protein-5 [CRMP5] paraneoplastic chorea associated with and small-cell lung cancer and thymoma) they are markers of a T-cell effector mediated injury as they are inaccessible to immune attack in situ, but peptides from intracellular proteins are displayed on upregulated MHC class 1 molecules in a pro-inflammatory cytokine milieu and then accessible to peptide specific cytotoxic T-cells. Associated neural autoantibodies include: ANNA-2(anti-Ri) (antineuronal nuclear autoantibody type 2); CRMP5(anti-CV2) (collapsin response mediator protein 5); GABABR (Gamma-aminobutyric-acid autoantibodies); NMDA-R (N-methyl-D-aspartate receptor autoantibodies); Ma2;